Melanoma represents the most aggressive and the deadliest form of skin cancer. Current
therapeutic approaches include surgical resection, chemotherapy, photodynamic therapy …

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the
gastrointestinal tract. The majority of GISTs harbor gain of function mutations in either KIT or …

Highlights•This clinical practice guideline provides key recommendations on the
management of gastrointestinal stromal tumours.•Recommendations have been agreed …

Background Targeting of KIT and PDGFRA with imatinib revolutionised treatment in
gastrointestinal stromal tumour; however, PDGFRA Asp842Val (D842V)-mutated …

Mutations play a fundamental role in the development of cancer, and many create targetable
vulnerabilities. There are both public health and basic science benefits from the …

Owing to the dysregulation of protein kinase activity in many diseases including cancer, the
protein kinase enzyme family has become one of the most important drug targets in the 21st …

Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted
incidence of around 1/100 000/year [1]. This only covers clinically relevant GISTs, since, if …

Background Resistance to approved inhibitors of KIT proto-oncogene, receptor tyrosine
kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a clinical challenge …

Receptor tyrosine kinases (RTKs) play an important role in a variety of cellular processes
including growth, motility, differentiation, and metabolism. As such, dysregulation of RTK …

When gastrointestinal stromal tumour (GIST), the most common form of sarcoma, was first
recognized as a distinct pathological entity in the 1990s, patients with advanced-stage …